Merck & Co. has entered into a partnership with the Coalition for Epidemic Preparedness Innovations (CEPI) to develop an updated version of its Ervebo® Ebola vaccine. The collaboration is backed by a $30 million program that will fund research, clinical testing, and manufacturing scale‑up aimed at reducing costs and expanding access in low‑ and middle‑income countries.
The updated vaccine will incorporate a new adjuvant that is expected to enhance immune response and allow for a single‑dose regimen, potentially lowering production costs and simplifying distribution. CEPI will provide technical expertise and global distribution channels, while Merck will supply its established manufacturing facilities and regulatory experience. The partnership’s development timeline targets completion of phase 2 trials by the end of 2027, with a view to seeking regulatory approval in 2028.
Merck’s decision to invest in this program aligns with its broader strategy to diversify beyond its flagship oncology drug Keytruda. The company’s vaccine portfolio, which includes Ervebo® and a range of other licensed vaccines, is positioned to capture growing demand for affordable vaccines in emerging markets. The $30 million commitment represents a significant but focused investment, with $15 million earmarked for preclinical research, $10 million for clinical development, and $5 million for manufacturing scale‑up and supply‑chain optimization.
Management emphasized the partnership’s role in strengthening Merck’s global health footprint. “By working with CEPI, we can accelerate the delivery of a more affordable Ebola vaccine to the regions that need it most,” said Rob Davis, Merck’s Chairman and CEO. “This initiative reflects our commitment to public health and our strategy to broaden our vaccine portfolio beyond oncology.”
The partnership is expected to enhance Merck’s competitive positioning in the global vaccine market, providing a new revenue stream while reinforcing its reputation as a leader in public‑health innovation. The $30 million program is a long‑term investment that may not generate immediate revenue but is likely to yield strategic benefits in terms of market access, regulatory goodwill, and future sales in low‑ and middle‑income countries.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.